Artivion’s (AORT) “Buy” Rating Reaffirmed at Needham & Company LLC

Artivion (NYSE:AORT)‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. They presently have a $58.00 target price on the stock. Needham & Company LLC’s target price suggests a potential upside of 66.02% from the company’s current price.

A number of other research firms also recently weighed in on AORT. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Canaccord Genuity Group cut their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research report on Thursday, March 5th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Artivion presently has an average rating of “Moderate Buy” and a consensus target price of $50.47.

Artivion Stock Up 4.4%

Shares of AORT traded up $1.49 during midday trading on Tuesday, hitting $34.94. The stock had a trading volume of 617,325 shares, compared to its average volume of 417,763. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of 174.87 and a beta of 1.63. The company has a 50 day simple moving average of $37.52 and a two-hundred day simple moving average of $41.83. Artivion has a twelve month low of $21.97 and a twelve month high of $48.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. Artivion’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, analysts anticipate that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling

In other Artivion news, SVP Jean F. Holloway sold 8,962 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the transaction, the senior vice president owned 185,095 shares of the company’s stock, valued at $7,033,610. The trade was a 4.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Lance A. Berry sold 6,316 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $238,618.48. Following the transaction, the executive vice president directly owned 210,827 shares in the company, valued at $7,965,044.06. This trade represents a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 133,043 shares of company stock valued at $4,977,158 in the last ninety days. 7.60% of the stock is owned by company insiders.

Institutional Trading of Artivion

A number of large investors have recently added to or reduced their stakes in AORT. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion in the 3rd quarter valued at about $27,000. Aster Capital Management DIFC Ltd grew its holdings in Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares during the period. Rockefeller Capital Management L.P. increased its position in Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares during the last quarter. Larson Financial Group LLC raised its stake in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares during the period. Finally, USA Financial Formulas raised its stake in Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after buying an additional 703 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.